Description: MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company unlocking the potential of sonelokimab, the first investigational Nanobody® for the treatment of inflammation, to revolutionize outcomes for patients. Sonelokimab optimally inhibits IL-17A and IL-17F inhibition to treat inflammatory diseases, by independently inhibiting the naturally-occurring IL-17 A/A, A/F and F/F dimers that drive inflammation in patients. The Company’s focus is on inflammatory diseases with a major unmet need with lead indications currently progressing into Phase 2 trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis or radiographic axial spondyloarthritis. MoonLake is headquartered in Zug, Switzerland.
Home Page: www.moonlaketx.com
MLTX Technical Analysis
Dorfstrasse 29
Zug,
6300
Switzerland
Phone:
Officers
| Name | Title |
|---|---|
| Dr. Jorge Santos da Silva | Co-Founder, CEO & Director |
| Dr. Kristian Reich | Co-Founder & Chief Scientific Officer |
| Mr. Matthias Bodenstedt | Chief Financial Officer |
| Mr. Oliver Daltrop | Chief Technical Officer |
| Ms. Nuala Brennan | Chief Clinical Devel. Officer |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2020-10-20 |
| Fiscal Year End: | December |
| Full Time Employees: | 0 |